Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
Robin Emsley, Sanja Kilian Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa Abstract: The course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and...
Guardado en:
Autores principales: | Emsley R, Kilian S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f8da9707275e4d8d8414b5c2a7803391 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley R, et al.
Publicado: (2017) -
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021) -
Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso C, et al.
Publicado: (2017) -
Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si T, et al.
Publicado: (2019) -
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao JP, et al.
Publicado: (2017)